JERSEY CITY, N.J., May 24, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovativetherapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at American Society for Microbiology (ASM) Microbe 2018, June 7-11, 2018, in Atlanta.
Title: Morphological Effect of SCY-078 and Caspofungin on Different Echinocandin-Resistant Candida SpeciesPoster Presentation #: 497Presenter: Mahmoud Ghannoum, PhD
Title: In Vitro Activity of SCY-078 in Combination with Isavuconazole Or Amphotericin B against Medically Important MouldsPoster Presentation #: 498Presenter: Vidmantis Petraitis, PhD
Title: Does Sabouraud Dextrose Broth, Compared to RPMI, Differentiate Susceptibility between Resistant and Susceptible C. glabrata and C. albicans Isolates to SCY-078, A Novel ?-D-Glucan Synthase Inhibitor and Caspofungin?Poster Presentation #: 506Presenter: Mahmoud Ghannoum, PhD
The ASM Microbe 2018 posters will be presented at the session "Antifungal Agents and Resistance: Agents to Treat Fungal Infections" on Friday, June 8, from 11:00-13:00 ET, and will be available on the SCYNEXIS website following the event.
About SCYNEXISSCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Investor RelationsSusan KimArgot PartnersTel: firstname.lastname@example.org
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: email@example.com
View original content:http://www.prnewswire.com/news-releases/scynexis-to-present-scy-078-data-at-asm-microbe-2018-300652073.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All